Page last updated: 2024-12-07

frovatriptan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Frovatriptan is a selective 5-HT1B/1D receptor agonist used for the treatment of migraine headaches. It is thought to work by constricting blood vessels in the brain and blocking the release of pain-producing substances. Frovatriptan is synthesized through a multi-step process involving several chemical reactions. It was developed as a treatment option for migraines due to its effectiveness in reducing headache pain and associated symptoms like nausea and sensitivity to light. Frovatriptan is studied for its potential to be a safe and effective treatment for migraines, with researchers investigating its efficacy, safety profile, and optimal dosing strategies.'

Cross-References

ID SourceID
PubMed CID77992
CHEMBL ID1279
CHEBI ID134991
SCHEMBL ID34410
MeSH IDM0281019

Synonyms (49)

Synonym
BIDD:PXR0142
bdbm50073689
(r)-6-methylamino-6,7,8,9-tetrahydro-5h-carbazole-3-carboxylic acid amide
unii-h82q2d5wa7
h82q2d5wa7 ,
frovatriptan [inn:ban]
rilamig
auradol
miguard
frova
sb-209509
allegro
158747-02-5
(3r)-3-(methylamino)-2,3,4,9-tetrahydro-1h-carbazole-6-carboxamide
frovatriptan
DB00998
1h-carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (r)-
sb 209509
(r)-5,6,7,8-tetrahydro-6-(methylamino)carbazole-3-carboxamide
hsdb 7363
1h-carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (3r)-
CHEBI:134991
allergo filmtabletten
CHEMBL1279 ,
allergo filmtabletten (tn)
frovatriptan (inn)
D07997
(6r)-6-(methylamino)-6,7,8,9-tetrahydro-5h-carbazole-3-carboxamide
3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
frovatriptan [inn]
frovatriptan [who-dd]
frovatriptan [vandf]
frovatriptan [mart.]
frovatriptan [mi]
frovatriptan [hsdb]
gtpl7191
(3r)-3-(methylamino)-2,3,4,9-tetrahydro-1h-carbazole-6-carboximidic acid
SCHEMBL34410
DTXSID0023080 ,
Q410195
NCGC00408835-01
r-frovatriptan
EN300-24114152
HY-B1658
CS-0013614
frovatriptan (mart.)
dtxcid703080
n02cc07
frovatriptanum

Research Excerpts

Overview

Frovatriptan is a triptan characterized by a high affinity for 5-HT1B/1D receptors and a long half-life. It is a potent anti-migraine agent with unfavourable slow onset of action, available on the market as film-coated tablets.

ExcerptReferenceRelevance
"Frovatriptan is a second generation triptan with strong 5-HT1B/1D serotonergic agonism and low 5-HT1A/7 receptor affinity, while almotriptan possesses not only the typical 5-HT1B/1D receptor agonist activity, but shows an affinity to the 5-HT1F receptor."( Effects of new generation triptans - frovatriptan and almotriptan - on hemodynamic parameters in intact male and female rats.
Getova, D; Hrischev, P; Nikolova, J; Saracheva, K; Topolov, M; Vasileva, L, 2020
)
1.55
"Frovatriptan is a potent anti-migraine agent with unfavourable slow onset of action, available on the market as film-coated tablets."( Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management.
Furlanetto, S; Mennini, N; Mura, P; Orlandini, S; Pasquini, B, 2018
)
2.16
"Frovatriptan is a triptan characterized by a high affinity for 5-HT1B/1D receptors and a long half-life contributing to a more sustained and prolonged action than other triptans. "( The efficacy and tolerability of frovatriptan and dexketoprofen for the treatment of acute migraine attacks.
Allais, G; Benedetto, C; De Lorenzo, C; Rolando, S, 2014
)
2.13
"Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours)."( Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine.
Allais, G; Benedetto, C, 2016
)
1.52
"Frovatriptan is a 5-HT(1B/1D) agonist demonstrating consistently effective headache relief at a low dose of 2.5 mg. "( Frovatriptan: pharmacological differences and clinical results.
Rapoport, AM, 2001
)
3.2
"Frovatriptan is a potent 5-HT(1B/1D) receptor agonist and has the highest 5-HT(1B) potency in the triptan class. "( Frovatriptan: a review.
Goldstein, J, 2003
)
3.2
"Frovatriptan is a new selective 5HT(1B/1D) receptor agonist indicated for short-term management of migraine."( A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.
Elkind, AH; Keywood, C; Schreiber, C; Silberstein, SD, 2004
)
1.36
"Frovatriptan is a selective 5-HT(1B/1D) receptor agonist available for acute treatment of migraine in adults (18 years and older). "( Pharmacokinetics of frovatriptan in adolescent migraineurs.
Elkind, AH; Ishkanian, G; Wade, A, 2004
)
2.09
"Frovatriptan is a 5-HT(1B/1D) receptor agonist that belongs to the triptan therapeutic class. "( Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine.
Elkind, AH; MacGregor, EA, 2008
)
3.23
"Frovatriptan is a new 5-HT(1B/1D) agonist developed for the treatment of migraine."( Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan.
Comer, MB, 2002
)
2.01
"Frovatriptan is a new 5-hydroxytryptamine (5-HT)(1B/1D) agonist. "( Frovatriptan: a review of drug-drug interactions.
Buchan, P; Freestone, S; Oliver, SD; Stewart, AJ; Wade, A; Ward, C, 2002
)
3.2
"Frovatriptan is a new 5-hydroxytryptamine (5-HT)(1B/1D) receptor agonist being developed for the acute treatment of migraine with or without aura. "( Clinical efficacy of frovatriptan: placebo-controlled studies.
Cady, R; Géraud, G; Goldstein, J; Keywood, C; Ryan, R, 2002
)
2.08
"Frovatriptan is a new triptan developed for the acute treatment of migraine. "( Dose range-finding studies with frovatriptan in the acute treatment of migraine.
Goldstein, J; Keywood, C; Rapoport, A; Ryan, R, 2002
)
2.04
"Frovatriptan is a new, selective serotonin agonist (triptan) developed for the acute treatment of migraine. "( Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Géraud, G; Keywood, C; Spierings, EL, 2002
)
2.05

Effects

Frovatriptan has a longer half-life and lower headache recurrence rates compared with other triptans.

Frovatriptan has a longer half-life and lower headache recurrence rates compared with other triptans. It has no inhibiting or inducing effects on cytochrome P450 isoenzymes and is only slightly bound to plasma proteins; thus it has a low potential for drug interactions.

ExcerptReferenceRelevance
"Frovatriptan has a longer half-life and lower headache recurrence rates compared with other triptans."( The evolving management of migraine.
Ashkenazi, A; Silberstein, SD, 2003
)
1.04
"Frovatriptan has a distinctive pharmacological and pharmacokinetic profile compared with sumatriptan. "( Frovatriptan for the acute treatment of migraine: a dose-finding study.
Goldstein, J; Keywood, C, 2002
)
3.2
"Frovatriptan has been developed in order to improve safety and efficacy of triptans. "( Pharmacokinetic evaluation of frovatriptan.
Casolla, B; Lala, N; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2011
)
2.1
"Frovatriptan has no inhibiting or inducing effects on cytochrome P450 isoenzymes and is only slightly bound to plasma proteins; thus it has a low potential for drug interactions."( Frovatriptan: a review.
Goldstein, J, 2003
)
2.48
"Frovatriptan has been well tolerated in humans and efficacious in reducing headache pain and duration in clinical trials, which have also indicated that dose adjustments for age or gender are not necessary for the drug."( Frovatriptan: a selective type 1B/1D serotonin receptor agonist for the treatment of migraine headache.
Cole, P; Rabasseda, X, 2002
)
2.48
"Frovatriptan has a longer half-life and lower headache recurrence rates compared with other triptans."( The evolving management of migraine.
Ashkenazi, A; Silberstein, SD, 2003
)
1.04
"Frovatriptan has no clinically significant pharmacokinetic interactions with drugs used for migraine prophylaxis or with commonly prescribed medications."( Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine.
Balbisi, EA, 2004
)
2.49
"Frovatriptan has been effective and well tolerated over a wide range of doses in randomised, double-blind, placebo-controlled acute migraine trials and long-term, open-label trials."( Frovatriptan review.
Markus, F; Mikko, K, 2007
)
2.5
"Frovatriptan has a distinctive pharmacological and pharmacokinetic profile compared with sumatriptan. "( Frovatriptan for the acute treatment of migraine: a dose-finding study.
Goldstein, J; Keywood, C, 2002
)
3.2

Actions

ExcerptReferenceRelevance
"Frovatriptan blocked the increase in headache score over the placebo during HFIs."( Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines.
Clark, JW; Coffee, AL; Hansen, DJ; Hill, AJ; Kuehl, TJ; Sulak, PJ, 2014
)
1.37

Treatment

ExcerptReferenceRelevance
"Frovatriptan treatment produced an adverse events profile similar to that of placebo, and in a direct comparison study was better tolerated than sumatriptan 100 mg."( Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Géraud, G; Keywood, C; Spierings, EL, 2002
)
1.33

Toxicity

Frovatriptan treatment produced an adverse events profile similar to that of placebo, and in a direct comparison study was better tolerated than sumatripten 100 mg. The incidence of adverse events was higher in the frov atriptan-treated patients than in the patients who took placebo (47% versus 34%) and the spectrum of adverse event was similar.

ExcerptReferenceRelevance
" Safety and tolerability were assessed through the collection of adverse events, monitoring of heart rate and blood pressure performance of 12-lead electrocardiogram, hematology screen, and blood chemistry studies."( Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Géraud, G; Keywood, C; Spierings, EL, 2002
)
0.61
" The incidence of adverse events was higher in the frovatriptan-treated patients than in the patients who took placebo (47% versus 34%) and the spectrum of adverse events was similar."( Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Géraud, G; Keywood, C; Spierings, EL, 2002
)
0.86
" Frovatriptan treatment produced an adverse events profile similar to that of placebo, and in a direct comparison study was better tolerated than sumatriptan 100 mg."( Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan.
Géraud, G; Keywood, C; Spierings, EL, 2002
)
1.52
" Adverse events, serious adverse events, vital signs, cardiovascular events, electrocardiograms, and laboratory parameters were assessed and recorded periodically and summarized using descriptive statistics."( Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
Brandes, JL; Czapinski, P; Jeka, S; MacGregor, EA; Pawsey, S; Shaw, B; Silberstein, S, 2009
)
0.61
" Major reasons for discontinuation in Study 1 included adverse events (5%, double-blind period) and "other" (10% double-blind period and 5% open-label period)."( Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
Brandes, JL; Czapinski, P; Jeka, S; MacGregor, EA; Pawsey, S; Shaw, B; Silberstein, S, 2009
)
0.61
" Adverse events were generally mild or moderate in severity, there was no evidence of an increased risk of cardiovascular adverse events relative to acute treatment, and rebound headache was not evident."( Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
Brandes, JL; Czapinski, P; Jeka, S; MacGregor, EA; Pawsey, S; Shaw, B; Silberstein, S, 2009
)
0.61
" In AT1, which was previously published in part, group differences in adverse events (AEs) were analyzed using the Fisher exact test, and response rates were compared using logistic regression."( Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies.
Campbell, JC; Hu, X; MacGregor, EA; Pawsey, SP, 2010
)
0.66
" The most common adverse events in adolescents were headache, acne, and nasopharyngitis."( Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial.
Fang, H; Gooderham, M; Harada, K; Hebert, AA; Hordinsky, M; Kwon, O; Law, E; Murashkin, N; Takiya, L; Tran, H; Wajsbrot, D; Wolk, R; Zwillich, SH,
)
0.13

Pharmacokinetics

Frovatriptan was tested in adolescent migraineurs after a single 2.3-hour session. The terminal half-life for frovatripan was longer than rizatripta (29.3 hours)

ExcerptReferenceRelevance
"Preclinical data suggest that the pharmacokinetic profile of frovatriptan may differ from that of the currently available triptans."( Clinical pharmacokinetics of frovatriptan.
Buchan, P; Keywood, C; Wade, A; Ward, C, 2002
)
0.85
" The relatively long terminal elimination half-life (about 26 hours) confers good systemic exposure and may produce a long duration of therapeutic action, thus reducing migraine recurrence and the need for redosing."( Clinical pharmacokinetics of frovatriptan.
Buchan, P; Keywood, C; Wade, A; Ward, C, 2002
)
0.61
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic parameters were determined using a noncompartmental approach."( Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.
Boyce, M; Pawsey, S; Wade, A; Warrington, S; Whale, H, 2009
)
0.64
" A systematic approach is used to discuss the pharmacodynamic and pharmacokinetic aspects of frovatriptan, considering the emerging data on the clinical efficacy of frovatriptan in the treatment of migraine and cluster headaches."( Pharmacokinetic evaluation of frovatriptan.
Casolla, B; Lala, N; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2011
)
0.88
" Preclinical data suggest that the pharmacokinetic profile of frovatriptan may differ from other available triptans."( Pharmacokinetic evaluation of frovatriptan.
Casolla, B; Lala, N; Lionetto, L; Martelletti, P; Negro, A; Simmaco, M, 2011
)
0.9
" Although previous studies have independently compared the efficacy of these agents, contemporaneous data examining both pharmacokinetic (PK) properties and efficacy in parallel have not previously been available."( Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.
Egan, CG; Mogavero, S; Savi, L, 2014
)
0.67
"3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29."( Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.
Egan, CG; Mogavero, S; Savi, L, 2014
)
0.94

Compound-Compound Interactions

ExcerptReferenceRelevance
" This may be particularly the case when triptan therapy is combined with a nonsteroidal anti-inflammatory drug (NSAID)."( Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura.
Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Cortelli, P; Curone, M; D'Onofrio, F; Frediani, F; Omboni, S; Pezzola, D; Reggiardo, G; Sette, G; Tullo, V; Valguarnera, F; Zava, D, 2014
)
0.68

Bioavailability

ExcerptReferenceRelevance
"Oral bioavailability of frovatriptan is 22% to 30%, and although the time to maximum concentration is typically 2 to 3 hours, approximately 60% to 70% of plasma maximum concentration is achieved within 1 hour of dosing."( Clinical pharmacokinetics of frovatriptan.
Buchan, P; Keywood, C; Wade, A; Ward, C, 2002
)
0.91
" This is balanced by an average Tmax of 2-3 h, a low degree of lipophilicity and a low oral bioavailability of 24-30%."( Frovatriptan: pharmacological differences and clinical results.
Rapoport, AM, 2001
)
1.75
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

Frovatriptan can be taken without regard for food intake, and because of the large therapeutic margin and shallow dose-response curve, there is no need for dosage adjustment in the elderly, in women taking a combined oral contraceptive, in patients with mild-to-severe renal impairment.

ExcerptRelevanceReference
"5, 5, 10, 20, and 40 mg are equally effective in relieving headache with no evidence of a dose-response relationship."( Frovatriptan for the acute treatment of migraine: a dose-finding study.
Goldstein, J; Keywood, C, 2002
)
1.76
" Studies of frovatriptan in isolated human arteries demonstrated a lower threshold for constriction of cerebral than coronary vasculature and a bell-shaped dose-response curve was apparent in the coronary arteries."( Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan.
Comer, MB, 2002
)
0.95
"Frovatriptan can be taken without regard for food intake, and because of the large therapeutic margin and shallow dose-response curve, there is no need for dosage adjustment in the elderly, in women taking a combined oral contraceptive, in patients with mild-to-severe renal impairment, mild-to-moderate hepatic impairment, or according to gender."( Clinical pharmacokinetics of frovatriptan.
Buchan, P; Keywood, C; Wade, A; Ward, C, 2002
)
2.05
"5 mg, no dose-response relationship was observed for any efficacy parameters."( Dose range-finding studies with frovatriptan in the acute treatment of migraine.
Goldstein, J; Keywood, C; Rapoport, A; Ryan, R, 2002
)
0.6
"In all three studies, headache response 2 hours after frovatriptan dosing was significantly greater than that seen with placebo (P < or = ."( Clinical efficacy of frovatriptan: placebo-controlled studies.
Cady, R; Géraud, G; Goldstein, J; Keywood, C; Ryan, R, 2002
)
0.88
" No dosage adjustments are necessary based on age or renal or hepatic impairment."( Frovatriptan: a review.
Goldstein, J, 2003
)
1.76
" Overall, the pharmacokinetic profile of frovatriptan in adolescents (12-17 years) is similar to that seen in adults, and dosing adjustments are unlikely to be needed."( Pharmacokinetics of frovatriptan in adolescent migraineurs.
Elkind, AH; Ishkanian, G; Wade, A, 2004
)
0.91
" Dosing was also random with respect to the menstrual cycle."( Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.
Boyce, M; Pawsey, S; Wade, A; Warrington, S; Whale, H, 2009
)
0.64
" Twice-daily dosing maintained more consistent drug concentrations than once-daily dosing and was well tolerated."( Pharmacokinetics of two 6-day frovatriptan dosing regimens used for the short-term prevention of menstrual migraine: A phase I, randomized, double-blind, placebo-controlled, two-period crossover, single-centre study in healthy female volunteers.
Boyce, M; Pawsey, S; Wade, A; Warrington, S; Whale, H, 2009
)
0.64
" SPF episodes at 24-h after early dosing were 25 % (Frova), 45 % (FroDex 25) and 41 % (FroDex 37."( Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group stu
Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Colombo, B; Comi, G; Cortelli, P; Curone, M; D'Arrigo, G; d'Onofrio, F; Frediani, F; Omboni, S; Sette, G; Tullo, V; Valguarnera, F, 2015
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
carbazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency2.68370.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.06200.00010.532610.0000AID3850
5-hydroxytryptamine receptor 1DHomo sapiens (human)Ki0.00440.00010.808710.0000AID4627
5-hydroxytryptamine receptor 1BHomo sapiens (human)Ki0.01030.00010.54859.2100AID4256
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 1Homo sapiens (human)Km61.90002.10005.39008.6000AID1769498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of miRNA transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of serotonin secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, GABAergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to cocaine5-hydroxytryptamine receptor 1BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1BHomo sapiens (human)
drinking behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to ethanol5-hydroxytryptamine receptor 1BHomo sapiens (human)
bone remodeling5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to mineralocorticoid5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to alkaloid5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to xenobiotic stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration5-hydroxytryptamine receptor 1BHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of synaptic vesicle exocytosis5-hydroxytryptamine receptor 1BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
nucleusPOU domain, class 2, transcription factor 1Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulumPOU domain, class 2, transcription factor 1Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 1Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexPOU domain, class 2, transcription factor 1Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
endoplasmic reticulum5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
calyx of Held5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonergic synapse5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 1BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (45)

Assay IDTitleYearJournalArticle
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1769498Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1769500Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID3850In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1864507Substrate activity at OCT1 (unknown origin) assessed as uptake ratio2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1864506Substrate activity at human OCT2 overexpressed in HEK293 cells assessed as uptake ratio incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1864493Substrate activity at human OCT3 overexpressed in HEK293 cells assessed as uptake ratio incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1769499Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4256In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4627In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1999Journal of medicinal chemistry, Feb-11, Volume: 42, Issue:3
N-Methyl-5-tert-butyltryptamine: A novel, highly potent 5-HT1D receptor agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (138)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (2.90)18.2507
2000's68 (49.28)29.6817
2010's55 (39.86)24.3611
2020's11 (7.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.50 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index5.69 (4.65)
Search Engine Demand Index107.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials41 (28.87%)5.53%
Reviews33 (23.24%)6.00%
Case Studies4 (2.82%)4.05%
Observational2 (1.41%)0.25%
Other62 (43.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Feasibility and Cost Description of Intensive Rehabilitation Involving New Technologies in Patients With Sub-acute Stroke:A Multicenter Single Arm Trial of the Swiss RehabTech Initiative [NCT03641651]15 participants (Actual)Interventional2018-08-31Completed
An Open Label Study to Assess the Safety, Tolerability and Efficacy of Frovatriptan in the Prevention of Menstrually Associated Migraine (MAM) Headaches. [NCT01035983]Phase 3550 participants (Actual)Interventional2003-12-31Completed
Frovatriptan as a Transitional Therapy in Medication Overuse Headache [NCT01044251]Phase 255 participants (Actual)Interventional2010-01-31Completed
18F-Fluoride PET Bone Scans Versus Traditional 99mTc-MDP Gamma Camera Bone Scans for the Diagnosis of Bone Metastases: a Blinded, Prospective Trial [NCT01254929]299 participants (Actual)Observational2010-12-31Completed
A Randomized, Single-Blind Pilot Study to Compare the Efficacy and Cost-Effectiveness of Frovatriptan vs. Topiramate for the Prevention of Migraine [NCT00846495]Phase 455 participants (Actual)Interventional2009-08-31Completed
Phase 3 Study to Assess the Efficacy and Safety of Frovatriptan [NCT00821483]Phase 3298 participants (Actual)Interventional2006-11-30Completed
A Pilot Trial Examining the Safety and Efficacy of Frovatriptan as a Preemptive Treatment for Fasting-Induced Migraine Headache [NCT00440232]74 participants (Actual)Interventional2007-07-31Completed
Prevention of Menstrual Migraines: Effects of Continuous Oral Contraceptives to Combination With Prophylactic Frovatriptan Use During Hormone Free Intervals [NCT00700128]30 participants (Actual)Interventional2008-06-30Completed
[NCT00644033]Phase 3579 participants (Actual)Interventional2001-06-30Completed
A Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, and Safety of Oral Frovatriptan in the Prevention on Menstrually-related Migraine (MRM) Headaches in a 'Difficult to Treat' Population [NCT00475514]Phase 3500 participants (Actual)Interventional2004-10-31Completed
Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment)Of Menstrual Migraine [NCT00904098]Phase 4192 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00440232 (2) [back to overview]Incidence of Fasting-induced Headache of Any Intensity
NCT00440232 (2) [back to overview]Time to Development of Headache of Any Intensity
NCT00846495 (8) [back to overview]Adverse Events Associated With Study Medications
NCT00846495 (8) [back to overview]Number of Headache Days Reported by Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate to Prevent Migraine
NCT00846495 (8) [back to overview]Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate
NCT00846495 (8) [back to overview]Cost of Frovatriptan vs. Topiramate as Preventive Treatment of Migraine
NCT00846495 (8) [back to overview]Number of Headache Days Each Month Following Initiation of Treatment With Study Medication
NCT00846495 (8) [back to overview]Participant Satisfaction With Study Medications
NCT00846495 (8) [back to overview]Participants With Greater Than 50% Reduction in Migraine Attacks and Headache Days Per Month Utilizing Each Treatment Paradigm
NCT00846495 (8) [back to overview]Quality of Life in Subjects Utilizing Each Treatment Paradigm
NCT03641651 (8) [back to overview]Correlation Between Scheduled and Performed Trainings
NCT03641651 (8) [back to overview]10m Walk Test= TMT Comfortable
NCT03641651 (8) [back to overview]Berg Balance Scale (BBS)
NCT03641651 (8) [back to overview]Box and Block Test
NCT03641651 (8) [back to overview]Functional Ambulation Categories (FAC)
NCT03641651 (8) [back to overview]Functional Independence Measurement (FIM) Generic Functional Performance
NCT03641651 (8) [back to overview]Stroke Impact Scale (SIS) Recovery
NCT03641651 (8) [back to overview]Walking Index of the Chedoke-McMaster Stroke Assessment Measure (CMSA)

Incidence of Fasting-induced Headache of Any Intensity

Incidence of fasting-induced headache of any intensity occurring at greater than 4 hours, but within 20 hours after onset of fasting (NCT00440232)
Timeframe: 20 hours

Interventionparticipants (Number)
Frovatriptan12
Placebo18

[back to top]

Time to Development of Headache of Any Intensity

Time to development of headache of any intensity in the 2 treatment arms (NCT00440232)
Timeframe: 20 hours

Interventionhours (Mean)
Frovatriptan17.388
Placebo17.06

[back to top]

Adverse Events Associated With Study Medications

Includes Adverse Events at or above 5% frequency per group. (NCT00846495)
Timeframe: Treatment Months 1 and 2

InterventionAdverse Events (Number)
Topiramate26
Frovatriptan11

[back to top]

Number of Headache Days Reported by Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate to Prevent Migraine

Measure the change in number of headache days between participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate to prevent migraine (NCT00846495)
Timeframe: Treatment Month 2

InterventionHeadache Days (Mean)
Topiramate4.75
Frovatriptan2.79

[back to top]

Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate

Compare number of migraine attacks reported by participants using frovatriptan in a preemptive treatment paradigm vs. daily topiramate during Treatment Period Month 2 (NCT00846495)
Timeframe: Treatment Month 2

InterventionMigraine attacks (Mean)
Topiramate1.35
Frovatriptan2.12

[back to top]

Cost of Frovatriptan vs. Topiramate as Preventive Treatment of Migraine

Average cost of study medication taken by each subject. Measured in dollars. (NCT00846495)
Timeframe: Treatment Months 1 and 2

,
InterventionDollars (US) (Mean)
Preventive Medication TakenRescue Medication TakenAll Study Medication Taken
Frovatriptan101.4159.94161.35
Topiramate343.5638.33381.89

[back to top]

Number of Headache Days Each Month Following Initiation of Treatment With Study Medication

Measure the change in number of headache days reported by participants during each treatment month following initiation of treatment with study medication (NCT00846495)
Timeframe: 2 Months

,
InterventionHeadache Days (Mean)
Treatment Month 1Treatment Month 2
Frovatriptan3.963.42
Topiramate4.201.75

[back to top]

Participant Satisfaction With Study Medications

"Participant satisfaction is measured by the Patient Perception of Migraine Questionnaire (PPMQ). Questions were categorized within 6 dimensions: Efficacy, Functionality, Ease of Use, Cost, Bothersomeness of Side Effects, and Total Score. Scores range from 0 to 100. Higher scores represent better satisfaction.~Participants completed the PPMQ 24 hours following each first dose of frovatriptan." (NCT00846495)
Timeframe: Treatment Month 2

,
InterventionScore on a Scale (Mean)
EfficacyFunctionalityEase of UseCostBothersomeness of Side EffectsTotal Score
Frovatriptan75.197776.364892.698959.088695.539881.1417
Topiramate76.785777.821491.660781.253695.178682.0925

[back to top]

Participants With Greater Than 50% Reduction in Migraine Attacks and Headache Days Per Month Utilizing Each Treatment Paradigm

Compare number of participants with greater than 50% reduction in migraine attacks and headache days from Baseline to Treatment Months 1 and 2 (NCT00846495)
Timeframe: 2 Months

,
InterventionParticipants (Number)
Migraine Attacks Treatment Month 1Headache Days Treatment Month 1Migraine Attacks Treatment Month 2Headache Days Treatment Month 2
Frovatriptan1391513
Topiramate1171516

[back to top]

Quality of Life in Subjects Utilizing Each Treatment Paradigm

Quality of Life is measured by the Migraine Specific Quality of Life Questionnaire (MSQ), which includes 3 dimensions: Role Function Restrictive (degree to which performance of daily activities is limited), Role Function Preventive (degree to which performance of daily activities is interrupted), and Emotional Function (frustration and helplessness due to migraine). Scores range from 0 to 100. For each dimension, a higher score indicates a better health status. Participants completed the MSQ at Randomization, and after Treatment Months 1 and 2. (NCT00846495)
Timeframe: Randomization, End of Treatment Month 1, End of Treatment Month 2

,
InterventionScore on a Scale (Mean)
Role Function Restrictive - BaselineRole Function Restrictive - Treatment Month 1Role Function Restrictive - Treatment Month 2Role Function Preventive - BaselineRole Function Preventive - Treatment Month 1Role Function Preventive - Treatment Month 2Emotional Function - BaselineEmotional Function - Treatment Month 1Emotional Function - Treatment Month 2
Frovatriptan59.8866.4871.8477.5079.2584.9664.7173.1875.10
Topiramate56.0080.2986.6477.7585.2593.9560.6780.0091.46

[back to top]

Correlation Between Scheduled and Performed Trainings

Adherence was operationalized by correlating planned trainings with trainings which were carried out by the participants. Due to the small sample size Spearman's rank correlation was used. (NCT03641651)
Timeframe: 4 weeks

Interventioncorrelation coefficient (Number)
Technology Arm0.56

[back to top]

10m Walk Test= TMT Comfortable

time needed to walk 10 m with Comfortable walking speed (NCT03641651)
Timeframe: Baseline and 4 weeks

Interventionseconds (Mean)
pre-interventionpost-intervention
Technology Arm28.619.0

[back to top]

Berg Balance Scale (BBS)

Observer based measurement of walking, standing and balance with 14 items/task to perform by the subject and rated each on scale from 0 to 4 (0= not able to do without help, 4 = can do safely and independently) score between 0 to 56, the more the better (NCT03641651)
Timeframe: Baseline and 4 weeks

Interventionunits on a scale (Mean)
pre-interventionpost-intervention
Technology Arm3239

[back to top]

Box and Block Test

"Measures broader motoric function of the arm and hand as a performance test. Subjects are required to grab and sort wooden blocks from one side of a small dividing wall set up on a table in front of the sitting subject to another side.~The unit of the measure is the amount of blocks transferred within 60 seconds." (NCT03641651)
Timeframe: Baseline and 4 weeks

Interventionblocks/60 sec (Mean)
pre-interventionpost-intervention
Technology Arm01

[back to top]

Functional Ambulation Categories (FAC)

Observer based measurement to rate the ability to walk independently. Rated from 0 to 6 (0= not able to walk independently, 6= can walk independently in every situation) (NCT03641651)
Timeframe: Baseline and 4 weeks

Interventionunits on a scale (Median)
pre-interventionpost-intervention
Technology Arm23.5

[back to top]

Functional Independence Measurement (FIM) Generic Functional Performance

observer based measurement of the subject performing basic functional tests, e.g. sitting-up from lying position, stand-up from sitting, walking, stair-climbing etc. Observer rate on a scale from 1 to 7 (1= totally dependent on aid, 7= totally independent) for each activity 18 items, that would led to a score from 18 (totally dependent) to 126 (totally independent) (NCT03641651)
Timeframe: Baseline and 4 weeks

Interventionunits on a scale (Mean)
pre-interventionpost-intervention
Technology Arm102104.5

[back to top]

Stroke Impact Scale (SIS) Recovery

"Questionnaire to be completed by the patient, regarding different parts in daily life: 1. physical problems: 4 items, 2. memory and thinking: 7 items, 3. mood and emotional control: 9 items, 4. communication and understanding: 7 items, 5.daily activities: 10 items, 6. mobility at home and community: 9 items, 7. hand function: 5 items, 8. participation in life: 8 items.~each item should be rated on on 5-point Lickert scale with 1= extremely difficult OR can't do at all OR no strength at all OR all the time AND 5 means: a lot of strength OR not difficult at all OR none of the time OR Question 9 regarding recovery from stroke rated on a scale from 0 - 100 (0= no recovery, 100= full recovery)" (NCT03641651)
Timeframe: Baseline and 4 weeks

Interventionunits on a scale (Mean)
pre-interventionpost-intervention
Technology Arm5065.5

[back to top]

Walking Index of the Chedoke-McMaster Stroke Assessment Measure (CMSA)

"The Walking Index consists of the 5 following items:~Walking indoors Walking outdoors, over rough ground, ramps, and curbs Walking outdoors several blocks Stairs Age and sex appropriate walking distance in meters for 2 minutes~scored on a 7-point scale (Stage 1 through 7, most impairment through to no impairment, respectively) score from 5 to 35 points, the more points the better" (NCT03641651)
Timeframe: Baseline and 4 weeks

Interventionunits on a scale (Mean)
pre-interventionpost-intervention
Technology Arm1619

[back to top]